{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:53Z","timestamp":1791041873739,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thalidomide is a teratogen in humans but not in rodents. It causes multiple birth defects including malformations of limbs, ears, and other organs. However, the species-specific mechanism of thalidomide teratogenicity is not completely understood. Reproduction of the human teratogenicity of thalidomide in rodents has previously failed because of the lack of a model reflecting human drug metabolism. In addition, because the maternal metabolic effect cannot be eliminated, the migration of unchanged thalidomide to embryos is suppressed, and the metabolic activation is insufficient to develop teratogenicity. Previously, we generated transchromosomic mice containing a human cytochrome P450 (CYP) 3A cluster in which the endogenous mouse<jats:italic>Cyp3a<\/jats:italic>genes were deleted. Here, we determined whether human CYP3A or mouse Cyp3a enzyme expression was related to the species difference in a whole embryo culture system using humanized CYP3A mouse embryos. Thalidomide-treated embryos with the human<jats:italic>CYP3A<\/jats:italic>gene cluster showed limb abnormalities, and human CYP3A was expressed in the placenta, suggesting that human CYP3A in the placenta may contribute to the teratogenicity of thalidomide. These data suggest that the humanized CYP3A mouse is a useful model to predict embryonic toxicity in humans.<\/jats:p>","DOI":"10.1038\/srep21419","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T11:27:29Z","timestamp":1456226849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model"],"prefix":"10.1038","volume":"6","author":[{"given":"Yasuhiro","family":"Kazuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kamataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Oshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"BFsrep21419_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/(SICI)1096-9926(199911)60:5<306::AID-TERA11>3.0.CO;2-Y","volume":"60","author":"MT Miller","year":"1999","unstructured":"Miller, M. T. & Stromland, K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60, 306\u2013321 (1999).","journal-title":"Teratology"},{"key":"BFsrep21419_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","volume":"363","author":"ME Franks","year":"2004","unstructured":"Franks, M. E., Macpherson, G. R. & Figg, W. D. Thalidomide. Lancet 363, 1802\u20131811 (2004).","journal-title":"Lancet"},{"key":"BFsrep21419_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.4161\/cc.7.9.5793","volume":"7","author":"J Knobloch","year":"2008","unstructured":"Knobloch, J. & Ruther, U. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7, 1121\u20131127 (2008).","journal-title":"Cell Cycle"},{"key":"BFsrep21419_CR4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","volume":"39","author":"M Melchert","year":"2007","unstructured":"Melchert, M. & List, A. The thalidomide saga. Int. J. Biochem. Cell Biol. 39, 1489\u20131499 (2007).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFsrep21419_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0022-3565(25)28564-0","volume":"173","author":"HJ Schumacher","year":"1970","unstructured":"Schumacher, H. J., Wilson, J. G., Terapane, J. F. & Rosedale, S. L. Thalidomide: disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species. J. Pharmacol. Exp. Ther. 173, 265\u2013269 (1970).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFsrep21419_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1124\/jpet.104.067793","volume":"310","author":"J Lu","year":"2004","unstructured":"Lu, J. et al. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J. Pharmacol. Exp. Ther. 310, 571\u2013577 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFsrep21419_CR7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0021-9258(18)60338-2","volume":"237","author":"T Omura","year":"1962","unstructured":"Omura, T. & Sato, R. A new cytochrome in liver microsomes. J. Biol. Chem. 237, 1375\u20131376 (1962).","journal-title":"J. Biol. Chem."},{"key":"BFsrep21419_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","volume":"39","author":"FP Guengerich","year":"1999","unstructured":"Guengerich, F. P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1\u201317 (1999).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFsrep21419_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/03602539409029789","volume":"26","author":"FJ Gonzalez","year":"1994","unstructured":"Gonzalez, F. J. & Gelboin, H. V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26, 165\u2013183 (1994).","journal-title":"Drug Metab. Rev."},{"key":"BFsrep21419_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/03602539409029800","volume":"26","author":"M Kitada","year":"1994","unstructured":"Kitada, M. & Kamataki, T. Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab. Rev. 26, 305\u2013323 (1994).","journal-title":"Drug Metab. Rev."},{"key":"BFsrep21419_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2165\/00003088-200443080-00001","volume":"43","author":"MR Syme","year":"2004","unstructured":"Syme, M. R., Paxton, J. W. & Keelan, J. A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 43, 487\u2013514 (2004).","journal-title":"Clin. Pharmacokinet."},{"key":"BFsrep21419_CR12","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1021\/tx900367p","volume":"23","author":"G Chowdhury","year":"2010","unstructured":"Chowdhury, G. et al. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem. Res. Toxicol. 23, 1018\u20131024 (2010).","journal-title":"Chem. Res. Toxicol."},{"key":"BFsrep21419_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1006\/abbi.1996.0214","volume":"329","author":"Y Li","year":"1996","unstructured":"Li, Y. et al. Establishment of transgenic mice carrying human fetus-specific CYP3A7. Arch. Biochem. Biophys. 329, 235\u2013240 (1996).","journal-title":"Arch. Biochem. Biophys."},{"key":"BFsrep21419_CR14","first-page":"641","volume":"57","author":"Y Li","year":"1997","unstructured":"Li, Y. et al. In vivo activation of aflatoxin B1 in C57BL\/6N mice carrying a human fetus-specific CYP3A7 gene. Cancer Res. 57, 641\u2013645 (1997).","journal-title":"Cancer Res."},{"key":"BFsrep21419_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/hmg\/dds468","volume":"22","author":"Y Kazuki","year":"2013","unstructured":"Kazuki, Y. et al. Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Hum. Mol. Genet. 22, 578\u2013592 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"BFsrep21419_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1289\/ehp.7618105","volume":"18","author":"DA New","year":"1976","unstructured":"New, D. A. Techniques for assessment of teratologic effects: embryo culture. Environ Health Perspect. 18, 105\u2013110 (1976).","journal-title":"Environ Health Perspect."},{"key":"BFsrep21419_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1469-185X.1978.tb00993.x","volume":"53","author":"DA New","year":"1978","unstructured":"New, D. A. Whole-embryo culture and the study of mammalian embryos during organogenesis. Biol. Rev. Camb. Philos. Soc. 53, 81\u2013122 (1978).","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"BFsrep21419_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/tera.1420280209","volume":"28","author":"CE Steele","year":"1983","unstructured":"Steele, C. E., Trasler, D. G. & New, D. A. An in vivo\/in vitro evaluation of the teratogenic action of excess vitamin A. Teratology 28, 209\u2013214 (1983).","journal-title":"Teratology"},{"key":"BFsrep21419_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0022-3565(25)27910-1","volume":"160","author":"H Schumacher","year":"1968","unstructured":"Schumacher, H., Blake, D. A., Gurian, J. M. & Gillette, J. R. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160, 189\u2013200 (1968).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFsrep21419_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/tx200005g","volume":"24","author":"H Yamazaki","year":"2011","unstructured":"Yamazaki, H. et al. In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. Chem. Res. Toxicol. 24, 287\u2013289 (2011).","journal-title":"Chem. Res. Toxicol."},{"key":"BFsrep21419_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1021\/tx300009j","volume":"25","author":"H Yamazaki","year":"2012","unstructured":"Yamazaki, H. et al. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice. Chem. Res. Toxicol. 25, 274\u2013276 (2012).","journal-title":"Chem. Res. Toxicol."},{"key":"BFsrep21419_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/BF01917926","volume":"35","author":"DA New","year":"1979","unstructured":"New, D. A. & Cockroft, D. L. A rotating bottle culture method with continuous replacement of the gas phase. Experientia 35, 138\u2013140 (1979).","journal-title":"Experientia"},{"key":"BFsrep21419_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12015-009-9064-2","volume":"5","author":"K Kulkeaw","year":"2009","unstructured":"Kulkeaw, K. et al. Application of whole mouse embryo culture system on stem cell research. Stem Cell Rev. 5, 175\u2013180 (2009).","journal-title":"Stem Cell Rev."},{"key":"BFsrep21419_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/00039896.1962.10663250","volume":"5","author":"W Lenz","year":"1962","unstructured":"Lenz, W. & Knapp, K. Thalidomide embryopathy. Arch. Environ. Health 5, 100\u2013105 (1962).","journal-title":"Arch. Environ. Health"},{"key":"BFsrep21419_CR25","first-page":"99","volume":"112","author":"W Lenz","year":"1966","unstructured":"Lenz, W. Malformations caused by drugs in pregnancy. Am. J. Dis. Child 112, 99\u2013106 (1966).","journal-title":"Am. J. Dis. Child"},{"key":"BFsrep21419_CR26","first-page":"45","volume":"11","author":"R Beckmann","year":"1961","unstructured":"Beckmann, R. & Kampf, H. H. On the quantitative determination and the qualitative demonstration of N-phthalylglutamic acid imide (thalidomide). Arzneimittelforschung 11, 45\u201347 (1961).","journal-title":"Arzneimittelforschung"},{"key":"BFsrep21419_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/8466","volume":"5","author":"T Parman","year":"1999","unstructured":"Parman, T., Wiley, M. J. & Wells, P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 5, 582\u2013585 (1999).","journal-title":"Nat. Med."},{"key":"BFsrep21419_CR28","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/2081208a0","volume":"208","author":"S Fabro","year":"1965","unstructured":"Fabro, S., Smith, R. L. & Williams, R. T. Thalidomide as a possible biological acylating agent. Nature 208, 1208\u20131209 (1965).","journal-title":"Nature"},{"key":"BFsrep21419_CR29","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1073\/pnas.78.4.2545","volume":"78","author":"GB Gordon","year":"1981","unstructured":"Gordon, G. B., Spielberg, S. P., Blake, D. A. & Balasubramanian, V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA 78, 2545\u20132548 (1981).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep21419_CR30","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato, R. J., Loughnan, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082\u20134085 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep21419_CR31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"BFsrep21419_CR32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265\u2013275 (1951).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep21419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep21419","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep21419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:43:39Z","timestamp":1748785419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep21419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,2,26]]}},"alternative-id":["BFsrep21419"],"URL":"https:\/\/doi.org\/10.1038\/srep21419","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]},"assertion":[{"value":"30 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21419"}}